New pill for psoriasis tested in everyday life
NCT ID NCT07256015
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study follows 200 Italian adults with moderate to severe psoriasis who are already taking the oral medication deucravacitinib. Researchers will track how well the drug controls skin symptoms, its safety, and how it affects quality of life over time. The goal is to see how the treatment works in real-world conditions, outside of a controlled clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Azienda Ospedaliera Universitaria Integrata Di Verona
RECRUITINGVerona, Verona, 37126, Italy
Contact
Conditions
Explore the condition pages connected to this study.